Core Insights - The company achieved 5.2% organic revenue growth in 2025, within its guidance range of 4% to 6%, despite weaker performance in the expert advisory business at Nelson Labs, which was offset by stronger volumes at Sterigenics [1][6] - The company has maintained financial consistency, marking its 20th consecutive year of revenue growth and sustaining EBITDA margins above 50% [2][4] - The company operates in a global market with an estimated serviceable addressable market of $18 billion and a footprint of 62 facilities worldwide, offering end-to-end solutions in sterilization and lab services [3][21] Financial Performance - The company generated over $200 million in free cash flow in 2025 and targets $500 million to $600 million over the next three years, with a significant drop in CapEx expected in 2027 [5][16][18] - The company reported improved interest expense of $9 million year-over-year and a lower tax rate, contributing to a $0.16 increase in adjusted earnings per share in 2025 [8] - The company achieved a 118-basis-point improvement in EBITDA margins in 2025, with a long-term target of 50 to 150 basis points of margin improvement from 2025 to 2027 [14][19] Segment Performance - Sterigenics experienced nearly 8% revenue growth and nearly 9% growth in EBITDA, driven by strong demand in medical devices and pharmaceuticals [10] - Nordion reported upper-single-digit revenue and EBITDA growth, with expectations of low- to mid-single-digit growth for the full year [11][10] - Nelson Labs is expected to see low-single-digit growth, with core sterilization-related routine testing anticipated to continue growing [12] 2026 Outlook - The company reiterated its constant-currency organic growth guidance of 5% to 6.5% for 2026, with Sterigenics expected to deliver mid- to high-single-digit growth [7][9] - Pricing is expected to be near the midpoint of the long-term guide of 3% to 4%, while volumes remain a significant factor influencing overall performance [12] Capital Allocation and Strategy - The company is focused on disciplined capital allocation, with improved net leverage approaching the target range of 2x to 3x, allowing for flexibility in debt paydown, M&A, or share repurchases [5][19] - Management is prioritizing organic growth while remaining opportunistic regarding capital allocation strategies [19]

Financial Data and Key Metrics Changes - Total company revenues increased by 9.1% to $311 million for Q3 2025, with adjusted EBITDA rising by 12.2% to $164 million, resulting in adjusted EBITDA margins of 52.7%, an increase of 147 basis points year over year [10][11] - Net income for Q3 2025 was $48 million, or $0.17 per diluted share, compared to $17 million, or $0.06 per diluted share in Q3 2024, with adjusted EPS increasing by $0.09 to $0.26 [11][12] Business Line Data and Key Metrics Changes - Sterigenics achieved 9.8% revenue growth to $193 million, driven by a favorable volume mix and increased pricing [12] - Nordion reported a revenue increase of 22.4% to $63 million, primarily due to volume and mix benefits [13] - Nelson Labs experienced a revenue decline of 5% to $56 million, impacted by a decrease in Expert Advisory Services, although segment income rose by 1.9% to $19 million [14] Market Data and Key Metrics Changes - The company reaffirmed its 2025 revenue outlook and raised its adjusted EBITDA outlook, expecting constant currency revenue growth of 4.5% to 6% and adjusted EBITDA growth of 6.75% to 7.75% [16][17] - Foreign currency is expected to contribute approximately 25 basis points to revenue and adjusted EBITDA growth [18] Company Strategy and Development Direction - The company emphasized its vital role in global healthcare, particularly with Nordion securing a 25-year renewal of its Class 1B operating license, ensuring a reliable supply of Cobalt-60 for critical sterilization processes [8][9] - The company is focused on maintaining a strong balance sheet, having paid down $75 million of debt and lowered interest expenses by approximately $13 million annually [7][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued recovery of volumes across Sterigenics and bioprocessing, with expectations for sustained growth [29] - The company noted that while Expert Advisory Services faced headwinds due to FDA funding issues, core lab testing is improving [48][49] Other Important Information - The company is on track to achieve its cumulative free cash flow commitment of $500 million to $600 million from 2025 through 2027 [20] - The effective tax rate on adjusted net income is expected to improve to 29% to 31% due to recent accounting guidance changes [19] Q&A Session Summary Question: Volume recovery in specific areas - Management noted consistent performance across Sterigenics and bioprocessing, with expectations for continued volume recovery [29] Question: Update on litigation - Management provided updates on various litigation cases, indicating progress in Illinois and Georgia, with no current personal injury claims in New Mexico [30][31] Question: Impact of government shutdown - Management stated minimal impact from the government shutdown, with some indirect effects on Expert Advisory Services [39] Question: Expert Advisory Services headwinds - Management confirmed that the lack of FDA activity is impacting Expert Advisory Services, contributing to a significant top-line impact [44] Question: Nordion revenue and margin outlook - Management explained that Nordion's revenue growth was accompanied by some margin pressure due to a shift in product mix, but overall margins remain strong [58] Question: Future pricing strategies - Management indicated that pricing contributions for Sterigenics are expected to stabilize around 3% to 4%, with potential for incremental pricing improvements over time [66][70] Question: Nelson Labs growth expectations - Management suggested that with the headwinds from Expert Advisory Services now in the past, Nelson Labs could reasonably expect to return to growth in 2026 [75]